Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, Andrea Sartore-Bianchi, Sabrina Arena, Piercarlo Saletti, Sara De Dosso, Luca Mazzucchelli, Milo Frattini, Salvatore Siena, Alberto Bardelli

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences